Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
ARK Investment Management founder-CEO Cathie Wood cheered Eli Lilly’s $3.8 billion AtaiBeckley acquisition on Sunday, calling it a “well-deserved” payoff for shareholders and a validation of Christian Angermayer’s psychedelic vision.ATAI stock rose 1% on Friday, adding 40% over the past five sessio…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
taiBeckley NASDAQ:ATAI, a New York-based developer of psychedelic-based treatments for mental health conditions, rose 34.70% premarket after Eli Lilly NYSE:LLY said it would acquire the company for up to $3.8 billion. Lilly will pay $6.75 a share in cash, or about $2.8 billion, a 26% premium to Wed…
(11:49 GMT) ATAI Life Sciences Price Target Raised to $17.00/Share From $15.00 by Canaccord Genuity
AtaiBeckley ATAI has drawn more investor attention in 2026 as its clinical calendar has sharpened. The stock’s rally reflects growing confidence in its psychiatric drug pipeline, but the investment case still depends on future data.The issue is whether the move reflects improving fundamentals or ex…
AtaiBeckley ATAI sits in a part of biotechnology where the investment debate is shifting. The company is not trying to win share in a mature antidepressant market with another chronic daily pill.Its pipeline instead reflects a broader push toward psychiatric treatments designed to work quickly, las…
AtaiBeckley ATAI is entering a catalyst-heavy period as its lead depression program moves closer to late-stage testing. The stock story is tied less to current revenue scale and more to whether its pipeline can validate new approaches in difficult mental health conditions.That setup gives growth-or…
